Velsipity (Etrasimod Arginine) Patent Expiration, LOE Window & CMS Spending

Velsipity (Etrasimod Arginine) by Pfizer: FDA Orange Book core substance LOE 2036-06-21, 0 AB generics, $3.3M 2024 CMS Part D & Medicaid spend, and $6,164 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN216956 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-06-21
Last Listed Patent or Exclusivity Date2036-06-21
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.3M
2024 Medicare Part D Spend$2.0M
2024 Medicaid Spend$1.3M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($6,164 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.